Articles of manufacture and methods for treatment using adoptive cell therapy

A method of treating a subject having marginal zone lymphoma (MZL), the method comprising administering to the subject a dose of T cells comprising T cells expressing a chimeric antigen receptor (CAR) that specifically binds to CD19, wherein:

• the dose of T cells comprises between at or about 2.5×107 viable CAR-expressing T cells and at or about 2×108 viable CAR-expressing T cells, inclusive;
• the dose of T cells comprising a ratio of CD4+ cells expressing the CAR to CD8+ cells expressing the CAR of between at or about 5:1 and at or about 1:5;
• administering the dose of T cells comprises administering a plurality of separate compositions, the plurality of separate compositions comprising a first composition comprising one of the CD4+ T cells and the CD8+ T cells and a second composition comprising the other of the CD4+ T cells and the CD8+ T cells, the first composition comprising at least 80% of one of the CD4+ T and the CD8+ T cells, and the second composition comprising at least 80% of the other of the CD4+ T and the CD8+ T cells, wherein the administration of the first composition and the second composition are carried out separately and from 0 to 6 hours apart;
• and
• the subject has relapsed following remission after treatment with, or become refractory to, one or more prior therapies.